NCODA Logo
BIRTH OF AN ORAL ONCOLYTIC

BIRTH OF AN ORAL ONCOLYTIC

THE QUEST FOR A NEW CANCER DRUG IS NOT FOR THE FAINT OF HEART  By  Brett Williams, PhD  With 10 new FDA approvals in the second half of 2019 alone, the toolbox of oral oncolytics is continuously expanding.   These new approvals present patients and providers alike...
THE UNDERLYING BIAS OF PHARMACOGENOMICS 

THE UNDERLYING BIAS OF PHARMACOGENOMICS 

RACIAL EXCLUSION IN CANCER CLINICAL TRIALS HAS LEFT BEHIND THE POPULATIONS MOST IN NEED OF TREATMENT  By Porscha Johnson, PharmD, CPGx  While research has led to profound advancements in cancer treatments — including antibody-drug conjugates and immunotherapy, as well...
BREAKING THROUGH FOR BETTER PATIENT CARE 

BREAKING THROUGH FOR BETTER PATIENT CARE 

NCODA partners with Prime Therapeutics to offer accreditation for its new MIP program    Since 2016, “Going Beyond the First Fill” has been NCODA’s credo and the primary focus of its Mission to create a patient-centered, safe, high-quality, comprehensive program to...
RISING TO THE CHALLENGE 

RISING TO THE CHALLENGE 

By Claudia S. Castro, PharmD, MS, BCOP, BCGP  The direct medical costs of oncology care in the U.S. was estimated by the Agency for Healthcare Research and Quality (AHRQ) in 2015 to be $80.2 billion.1  Much like the entire healthcare system, the high cost of oncology...